The correlation between DNA adducts and chromosomal aberrations was studied in the liver of benzidine (92875) exposed male ICR-Sprague- Dawley-mice after partial hepatectomy. Mice underwent partial hepatectomy, treatment with benzidine (0, 7.8, 19.5, 38.2, or 97.8mg/kg, intraperitoneally), and subcutaneous implantation of a 50 milligram 5-bromodeoxyuridine tablet at 58 hours. Intraperitoneal injection of colcemid (0.04 milligrams per 10 grams body weight) was administered at 70 hours. At 72 hours, mice were killed by cervical dislocation and the livers were removed and subjected to adduct analysis and cytogenic study. No chromosome type aberrations were observed. The majority of damage detected was observed as chromatid breaks. The results demonstrated a clastogenic effect for benzidine in-vivo. Relative adduct labeling (RAL) values were determined and a clear dose response relationship, linear for the dose range tested, was observed. Correlation between chromosomal aberration rate and net RAL was determined. The correlation coefficient for individual mice was 0.41 with a considerable scatter of individual points. Four outlying cases from the set contributed significantly to the variability of data. When the four points were removed, the correlation coefficient was 0.74. The authors conclude that benzidine/DNA adducts are associated with chromosomal aberrations in- vivo, corroborating the findings on associations between in-vitro mutagenesis and transformation and levels of particular carcinogen DNA adducts. Results indicated that DNA adduct levels may be important predictive factors in genotoxicity, including neoplasia.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.